Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

AIDS (London, England) - 30 Mar 2007

Nadler Jeffrey P, Berger Daniel S, Blick Gary, Cimoch Paul J, Cohen Calvin J, Greenberg Richard N, Hicks Charles B, Hoetelmans Richard M W, Iveson Kathy J, Jayaweera Dushyantha S, Mills Anthony M, Peeters Monika P, Ruane Peter J, Shalit Peter, Schrader Shannon R, Smith Stephen M, Steinhart Corklin R, Thompson Melanie, Vingerhoets Johan H, Voorspoels Ellen, Ward Douglas, Woodfall Brian

Abstract excerpt

OBJECTIVE: TMC125-C223 is an open-label, partially blinded, randomized clinical trial to evaluate the efficacy and safety of two dosages of etravirine (TMC125), a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant HIV-1. DESIGN: A total of 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mood Disorders

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Reverse Transcriptase Inhibitors

Share to Viral Load

Source

Identifiers

PMID: 17413684
DOI: 10.1097/QAD.0b013e32805e8776

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17413684-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.PMID 17413684Read ↗

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.Semantic proximity Read ↗

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.Semantic proximity Read ↗

Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).Semantic proximity Read ↗

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.Semantic proximity Read ↗

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.Semantic proximity Read ↗

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.Semantic proximity Read ↗

Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.Semantic proximity Read ↗

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.Semantic proximity Read ↗

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Semantic proximity Read ↗

Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.